79 related articles for article (PubMed ID: 25792711)
1. Mechanism of action of antiplatelet drugs on decompression sickness in rats: a protective effect of anti-GPIIbIIIa therapy.
Lambrechts K; Pontier JM; Mazur A; Theron M; Buzzacott P; Wang Q; Belhomme M; Guerrero F
J Appl Physiol (1985); 2015 May; 118(10):1234-9. PubMed ID: 25792711
[TBL] [Abstract][Full Text] [Related]
2. Effect of splenectomy on platelet activation and decompression sickness outcome in a rat model of decompression.
Lambrechts K; Pontier JM; Mazur A; Buzzacott P; Goanvec C; Wang Q; Theron M; Belhomme M; Guerrero F
Diving Hyperb Med; 2014 Sep; 44(3):154-7. PubMed ID: 25311322
[TBL] [Abstract][Full Text] [Related]
3. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
[TBL] [Abstract][Full Text] [Related]
4. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
[TBL] [Abstract][Full Text] [Related]
5. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
6. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
[TBL] [Abstract][Full Text] [Related]
7. Bubble-induced platelet aggregation in a rat model of decompression sickness.
Pontier JM; Vallée N; Bourdon L
J Appl Physiol (1985); 2009 Dec; 107(6):1825-9. PubMed ID: 19850726
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
[TBL] [Abstract][Full Text] [Related]
9. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
EPILOG Investigators
N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
[TBL] [Abstract][Full Text] [Related]
10. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.
Hamm CW; Heeschen C; Goldmann B; Vahanian A; Adgey J; Miguel CM; Rutsch W; Berger J; Kootstra J; Simoons ML
N Engl J Med; 1999 May; 340(21):1623-9. PubMed ID: 10341274
[TBL] [Abstract][Full Text] [Related]
11. Abciximab therapy is associated with increased platelet activation and decreased heparin dosage in patients with acute myocardial infarction.
Piorkowski M; Priess J; Weikert U; Jaster M; Schwimmbeck PL; Schultheiss HP; Rauch U
Thromb Haemost; 2005 Aug; 94(2):422-6. PubMed ID: 16113834
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological intervention against bubble-induced platelet aggregation in a rat model of decompression sickness.
Pontier JM; Vallée N; Ignatescu M; Bourdon L
J Appl Physiol (1985); 2011 Mar; 110(3):724-9. PubMed ID: 21212250
[TBL] [Abstract][Full Text] [Related]
13. Effects of the glycoprotein IIb/IIIa antagonist abciximab on thrombus formation and platelet function in cats with arterial injury.
Bright JM; Dowers K; Powers BE
Vet Ther; 2003; 4(1):35-46. PubMed ID: 12756634
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty.
Chen YH; Chen JW; Wu TC; Ding PY; Wang SP; Chang MS
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan; 63(1):8-15. PubMed ID: 10645045
[TBL] [Abstract][Full Text] [Related]
15. Clopidogrel reduces the inflammatory response of lung in a rat model of decompression sickness.
Bao XC; Chen H; Fang YQ; Yuan HR; You P; Ma J; Wang FF
Respir Physiol Neurobiol; 2015 Jun; 211():9-16. PubMed ID: 25784626
[TBL] [Abstract][Full Text] [Related]
16. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
[TBL] [Abstract][Full Text] [Related]
17. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
18. The glycoprotein IIb/IIIa receptor inhibitor (abciximab) in ST-segment elevation myocardial infarction.
Mesquita A; Baptista J; Palos J; Seabra-Gomes R
J Invasive Cardiol; 1999 Jun; 11(6):379-82. PubMed ID: 10745556
[TBL] [Abstract][Full Text] [Related]
19. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
Montalescot G; Barragan P; Wittenberg O; Ecollan P; Elhadad S; Villain P; Boulenc JM; Morice MC; Maillard L; Pansiéri M; Choussat R; Pinton P;
N Engl J Med; 2001 Jun; 344(25):1895-903. PubMed ID: 11419426
[TBL] [Abstract][Full Text] [Related]
20. Effects of abciximab on postresuscitation microcirculatory dysfunction after experimental cardiac arrest in rats.
Padosch SA; Teschendorf P; Fuchs A; del Valle y Fuentes D; Peter C; Popp E; Schneider A; Böttiger BW; Walther A
Resuscitation; 2010 Feb; 81(2):255-9. PubMed ID: 19944515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
